A phase III, multicenter, randomized, double-blind, placebo-controlled trial, evaluating maintenance Alpelisib in association with trastuzumab and pertuzumab for metastatic HER2+ BC with PIK3CA mutation, is ongoing [100]. Here, ERBB2 is linked to breast cancer.